ImmunityBio to Supply Recombinant BCG to Alleviate Tice BCG Shortage
Image Credit: Adobe Stock Images/FreshIdea.com The FDA has approved an expanded access program that will provide an alternative for Tice BCG—a Merck medication that treats various types of bladder cancer—to patients in the United States.1 A rise in global demand has resulted in supply shortages of Tice BCG in the country, which have impacted the treatment […]
Continue Reading